Validation of the global resource of eczema trials (GREAT database)

BMC Family Practice

Kim S Thomas³  Sherie Smith³  Finola Delamere⁴  Elizabeth Doney⁴  John R Ingram¹  Hywel C Williams³  Alison Devine²  Helen Nankervis³ 

[1] Department of Dermatology & Wound Healing, Institute of Infection & Immunity, Cardiff University, Cardiff, Wales;Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Bodelwyddan, Rhyl, UK;Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK;Cochrane Skin Group, Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK

关键词: Atopic dermatitis;    Eczema;    Randomised controlled trials;    Database;    Validation;   

Others  :  1142371
DOI  :  10.1186/s12895-015-0024-z

 received in 2014-08-08, accepted in 2015-02-19,  发布年份 2015

【 摘 要 】

Background

Eczema (syn. Atopic Eczema or Atopic Dermatitis) is a chronic, relapsing, itchy skin condition which probably results from a combination of genetic and environmental factors. The Global Resource of EczemA Trials (GREAT) is a collection of records of randomised controlled trials (RCTs) for eczema treatment produced from a highly sensitive search of six reference databases. We sought to assess the sensitivity of the GREAT database as a tool to save future researchers repeating extensive bibliographic searches.

Methods

All Cochrane systematic review on treatments for eczema and five non-Cochrane systematic reviews on eczema were identified as a reference set to assess the utility of the GREAT database in identifying randomised controlled trials (RCTs). RCTs included in the systematic reviews were checked for inclusion in the GREAT database by two independent authors. A third author resolved any disagreements.

Results

Five Cochrane and six non-Cochrane systematic reviews containing a total of 105 RCTs of eczema treatments were included. Of these, 95 fitted the inclusion criteria for the GREAT database and 88 were published from 2000 onwards. Of the 88 eligible studies, 92% were found in the GREAT database. Seven trials were not included in the GREAT database - two of these were reported within a review paper and one as an abstract with no trial results.

Conclusions

The sensitivity of the GREAT database for trials from 2000 onwards was high (75/88 trials, 94%). Sensitivity for the period prior to 2000 was less sensitive, due to differences in how the trials were identified prior to this time.

‘Dual’ filtering for new records has recently become part of the GREAT database methodology and should further improve the sensitivity of the database in time. The GREAT database can be considered as a primary source for future systematic reviews including randomised controlled trials of eczema treatments, but searches should be supplemented by checking reference lists for eligible trials, searching trial registries and contacting pharmaceutical companies for unpublished studies.

【 授权许可】

   
2015 Nankervis et al.; licensee BioMed Central.

【 参考文献 】

• [1]Williams HC, Wuthrich B: Atopic Dermatits. Edited by Williams HC. Cambridge University Press, Cambridge; 2000.
• [2]Nankervis H, Maplethorpe A, Williams HC: Mapping randomized controlled trials of treatments for eczema–the GREAT database (the Global Resource of EczemA Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010). BMC Dermatol 2011, 11:10. BioMed Central Full Text
• [3]Hoare C, Li Wan Po A, Williams H: Systematic review of treatments for atopic eczema. Health Technol Assess 2000, 4(37):1-191.
• [4]Mapping of systematic reviews of atopic eczema. [http://www.nottingham.ac.uk/research/groups/cebd/documents/methodological-resources/maponaewebsitefeb2013.pdf]
• [5]Futamura M, Thomas KS, Grindlay DJC, Doney EJ, Torley D, Williams HC: Mapping systematic reviews on atopic eczema—an essential resource for dermatology professionals and researchers. PLoS ONE 2013, 8(3):e58484.
• [6]Ashcroft DM, Chen LC, Garside R, Stein K, Williams HC: Topical pimecrolimus for eczema. Cochrane Database Syst Rev 2007, 4:CD005500.
• [7]Bath-Hextall F, Delamere FM, Williams HC: Dietary exclusions for established atopic eczema. Cochrane Database Syst Rev 2008, 1:CD005203.
• [8]Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC: Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008, 3:CD003871.
• [9]Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML: Probiotics for treating eczema. Cochrane Database Syst Rev 2008, 4:CD006135.
• [10]Ersser SJ, Latter S, Sibley A, Satherley PA, Welbourne S: Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev 2007, 3:CD004054.
• [11]Zhang W, Leonard T, Bath-Hextall F, Chambers CA, Lee C, Humphreys R, et al.: Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev 2005, 2:CD002291.
• [12]Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI: Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol 2011, 147(4):474-88.
• [13]Yin Z, Xu J, Luo D: Efficacy and tolerance of tacrolimus and pimecrolimus for atopic dermatitis: A meta-analysis. J Biomed Res 2011, 25(6):385-91.
• [14]Svensson A, Chambers C, Ganemo A, Mitchell SA: A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin 2011, 27(7):1395-406.
• [15]Simonart T, Kabagabo C, De Maertelaer V: Homoeopathic remedies in dermatology: a systematic review of controlled clinical trials. Br J Dermatol 2011, 165(4):897-905.
• [16]Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C: Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011, 164(2):415-28.
• [17]Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY: Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Aller Clin Immunol 2001, 108(4):651-2.
• [18]Novartis. A 4-week, randomized, multicenter, double-blind, vehicle-controlled, parallel-group clinical trial to evaluate the efficacy and safety of pimecrolimus cream 1% in the short-term treatment of patients with mild to moderate Atopic Dermatitis (Eczema). In: Novartis Trials Database. 2005.
• [19]Novartis. A 6-month, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of pimecrolimus 1% cream twice daily vs. standard of care in the management of mild to severe atopic dermatitis in adults.In: Novartis Trials Database. 2005.
• [20]Novartis. A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of pimecrolimus cream 1% in mild to moderate head and neck atopic dermatitis of patients intolerant of topical corticosteroid. In: Novartis Trials Database; 2006.
• [21]Novartis. Confirmatory study in pediatric patients with atopic dermatitis- multicenter, randomized, double-blind, parallel-group, vehicle-controlled study with a 26-weeks treatment phase to determine the efficacy, safety of pimecrolimus cream for long-term treatment of pediatric patients with atopic dermatitis. In: Novartis Trials Database. 2005.
• [22]Novartis. A multicenter, 5-week, randomized, double-blind, placebo controlled, parallel group study exploring the effects of pimecrolimus cream 1% (twice daily application) vs. placebo control (twice daily application) on the molecular and cellular profile of adult male patients with atopic dermatitis. In: Novartis Trials Database. 2006.
• [23]Clinical Trials Results database. [http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp]
• [24]Staab D, Kaufmann R, Brautigam M, Wahn U, Group CAC-S: Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents’ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol 2005, 16(6):527-33.
• [25]Thaci DF-HR, Foelster-Holst R, Hoger P, Kaufmann R, Brautigam M, Weidinger G, et al.: Pimecrolimus cream 1% is effective in the treatment of atopic eczema in infants irrespective of clinical score. J Eur Acad Dermatol Venereol 2003, 17(Suppl 3):2.37.
• [26]Kirjavainen PV, Salminen SJ, Isolauri E: Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003, 36(2):223-7.
• [27]Nakagawa H: Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig 2006, 26(5):235-46.
• [28]Siegfried EKN, Molina C, Kianifard F, Abrams K: Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. J Dermatol Treat 2006, 17(3):143-50.
• [29]Breneman D, Fleischer A Jr, Abramovits W, Farber H: Tacrolimus ointment with and without topical steroids in patients with moderate to severe atopic dermatitis. J Am Acad Dermatol 2006, 54(3, Suppl 1 AB88):832. Abstract
• [30]Hung SH, Lin YT, Chu CY, Lee CC, Liang TC, Yang YH, et al.: Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol 2007, 98(1):51-6.
• [31]Larsen FS, Simonsen L, Melgaard A, Wendicke K, Henriksen AS: An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm Venereol 2007, 87(1):62-8.
• [32]Ravenscroft JC, Layton AM, Eady EA, Murtagh MS, Coates P, Walker M, et al.: Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol 2003, 148(5):1010-7.
• [33]Polano MK, De Vries HR: Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica 1960, 120:191-9.
• [34]Nilsson EJ, Henning CG, Magnusson J: Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992, 27(1):29-34.
• [35]Leyden JJ, Marples RR, Kligman AM: Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974, 90(5):525-30.
• [36]Fattah AA, El-Shiemy S, Faris R, Tadros SS: A comparative clinical evaluation of a new topical steroid ‘halcinonide’ and hydrocortisone in steroid-responsive dermatoses. J Int Med Res 1976, 4(4):228-31.
• [37]Alltrials. [http://www.alltrials.net/]
• [38]Transfusion evidence library. [http://evidentiapublishing.com/transfusion-evidence-library/]